Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.66 |
| ▸ | F2 | P00734 | 2/20 | 0.64 |
| ▸ | F9 | P00740 | 1/20 | 0.64 |
| ▸ | PLAT | P00750 | 1/20 | 0.64 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947905 | 1.00 | F10 (0.66) | F10F2F9PLATKLKB1 | |
| SCHEMBL950595 | 1.00 | F10 (0.66) | F10F2F9PLATKLKB1 | |
| Hydrochloric Acid SCHEMBL949100 | 0.99 | F10 (0.65) | F10F2F9PLATKLKB1 | |
| SCHEMBL949851 | 0.91 | F10 (0.53) | F10F2F9PLATKLKB1 | |
| Hydrochloric Acid SCHEMBL949183 | 0.91 | F10 (0.53) | F10F2F9PLATKLKB1 | |
| Hydrochloric Acid SCHEMBL950701 | 0.91 | F10 (0.53) | F10F2F9PLATKLKB1 | |
| SCHEMBL948469 | 0.90 | F10 (0.65) | F10F2F9PLATKLKB1 | |
| SCHEMBL950188 | 0.89 | F10 (0.62) | F10F2F9PLATKLKB1 | |
| SCHEMBL948405 | 0.89 | F10 (0.64) | F10F2F9PLATKLKB1 | |
| SCHEMBL950932 | 0.89 | F10 (0.64) | F10F2F9PLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | claimed |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1564213-A1 | IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004736-A1 | Imidazole derivative, process for producing the same, and use | HRH4, F2, HRH2 | F10 545/4885F2 2/4885F9 57/4885 |
| US-20110009389-A1 | IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE | F2, H1-3, CYC1 | F10 490/4885F2 1/4885F9 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.